The debate focuses on the motion for access to psilocybin treatments, indicating a discussion on medical and therapeutic uses of psilocybin. The speaker expresses his interest in learning more about the topic.

Proposes urgent review of psilocybin's status under Misuse of Drugs Regulations 2001 to facilitate mental health treatment development and human brain research. Mentions historical use of psychedelics in medicine, challenges with current schedule 1 regulations for scientific research, patient experiences with PTSD, economic burden of depression in the UK, international advances in psilocybin therapy, and calls on government support.

The whole House will wish to commend the hon. Lady for her courage in bringing this matter before the House and for the way in which she has put her case this afternoon.

The hon. Member for Reigate emphasised the urgent need to reschedule psilocybin from its current Schedule 1 status to a more appropriate classification based on recent evidence of its therapeutic benefits in mental health treatments such as depression and PTSD. He noted that since 2017, when the ACMD was first asked to review psilocybin, over 40,000 people have taken their own lives due to depression and trauma. He highlighted that this Home Office-led policy inertia is unethical and counterproductive given the potential benefits for patients and the economy.

He emphasised the cross-party support for the debate and criticised the Government's approach to sending an inappropriate Minister. He highlighted the lack of research on psilocybin due to its schedule 1 status under UK law, noting that this status is based on preconceptions rather than evidence. Cowan mentioned the progress made in the USA and Australia regarding medical research with psilocybin and called for an urgent review by the Government.

Kruger supported the debate, acknowledging the speeches of Charlotte Nichols and Crispin Blunt. He highlighted studies suggesting psilocybin's efficacy in treating mental health conditions similar to or superior to pharmaceutical interventions like SSRIs. However, he expressed concern about dependency on prescribed drugs and the need for better withdrawal support systems. Kruger emphasised the complexity of mental health issues and cautioned against seeing psilocybin as a quick fix.

Blunt interjected to reinforce his earlier point about the existing studies showing evidence for the efficacy of psilocybin despite its schedule 1 status. He stressed that while there is already sufficient evidence to suggest psilocybin's benefits, further research and enabling treatments are necessary.

Expressed gratitude to colleagues and emphasised the importance of evidence-based drug law reform. Acknowledged cross-party support for sensible drug policies, particularly in relation to psilocybin rescheduling. Highlighted the need for policy changes based on current medical evidence rather than outdated perceptions. Criticised the UK Government's reluctance to adopt evidence-based approaches and mentioned safe consumption rooms as an example of missed opportunities. Emphasised the potential benefits of psilocybin for various health conditions, including mental health issues and menopause symptoms. Urged the Minister to reconsider drug scheduling laws in light of growing international support for reform.

In her speech, Karin Smyth emphasised the importance of an evidence-led and data-driven approach to the use of psilocybin and other treatments in the NHS. She highlighted the need for cross-departmental collaboration between Health and Home Office regarding controlled drugs licensing regime to support research and clinical trials. Smyth also questioned the Government's commitment to mental health, citing long waiting lists and supply issues with antidepressants. Labour’s proposed solutions included placing a mental health specialist in every school, doubling medical places, guaranteeing treatment within a month by recruiting more staff, and reforming the NHS to focus on early diagnosis and intervention.

The Government recognise the substantial interest in psilocybin and other psychedelic drugs. The debate seeks to address concerns about the regulatory framework, licensing costs, research facilitation, and cross-departmental coordination between Health and Social Care and Home Office. He acknowledged promising research on psilocybin's potential benefits for depression but emphasised that rigorous clinical trials are necessary before making it available for NHS prescribing. He highlighted the current process involving MHRA assessments and NICE evaluations. The Minister committed to working with the Advisory Council on the Misuse of Drugs (ACMD) to extend schedule 2 status for research purposes to all schedule 1 drugs, including psilocybin, aiming to reduce barriers to legitimate research while maintaining patient safety.

Inquired about the duties that took the Minister away from the debate and questioned why esketamine is approved in Scotland but not in England, highlighting discrepancies in drugs policy administration. He emphasised the need for a more streamlined approach to research and licensing of psychedelic drugs.

She criticised the current licensing regime that requires psilocybin to be added to another substance before it can be assessed as a medicine, arguing that this makes it difficult for legitimate research and development. She pointed out that psilocybin is the medicine itself and does not need to be compounded with other substances.

He highlighted additional costs beyond licensing, such as laboratory modifications required due to psilocybin's classification as a schedule 1 drug. This imposes significant financial barriers for researchers and laboratories.

Expresses disappointment in the Government’s lack of urgency regarding the ACMD review which has been ongoing since 2017, noting that at least 40,000 people have taken their own lives during this period. Grateful for the Minister's willingness to take the debate back to the appropriate minister but stresses the need for progress on the issue. Acknowledges and thanks Members who participated in making a clear case against Government inertia.